ALT Altimmune Inc

USD 4.3800 -0.57 (-11.52%)
As of 11:15AM EDT.
Icon

Altimmune Inc Stock Analysis and Price Target COMMON STOCK | Biotechnology | NSD

stockTargetAdvisor

Buy

Average User
Rating
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis

USD 4.95

-5.97 (-54.67)%

USD 0.54B

0.02B

USD 21.83(+341.08%)

USD 24.48 (+394.55%)

Icon

ALT

Altimmune Inc (USD)
COMMON STOCK | NSD
USD 4.3800
-0.57 (-11.52%)
As of 11:15AM EDT.
stockTargetAdvisor

Buy

Average User
Rating
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis

USD 0.54B

USD 24.48 (+394.55%)

USD 4.95

Altimmune Inc Stock Forecast

Show ratings and price targets of :
USD 21.83
(+341.08%)

Based on the Altimmune Inc stock forecasts from 5 analysts, the average analyst target price for Altimmune Inc is USD 21.83 over the next 12 months. Altimmune Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Altimmune Inc is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, Altimmune Inc’s stock price was USD 4.95. Altimmune Inc’s stock price has changed by -55.37% over the past week, -56.31% over the past month and -27.63% over the last year.

No recent analyst target price found for Altimmune Inc
No recent average analyst rating found for Altimmune Inc

Company Overview

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-al...Read More

https://altimmune.com

910 Clopper Road, Gaithersburg, MD, United States, 20878

52

December

USD

USA

Adjusted Closing Price

Loading...

Technical Indicators

Unadjusted Closing Price

Loading...

Assets

Top Holdings

Top Sectors

Top Regions

Share Volume

Loading...

Relative Performance

Symbol Capital Gain Dividend Return Total Return
Loading...

Stocks Similar To Altimmune Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN
Regeneron Pharmaceuticals Inc +0.51 (+0.07%) USD81.74B 20.08 12.07

ETFs Containing ALT

Symbol Name Weight Mer Price(Change) Market Cap
GERM
ETFMG Treatments Testing .. 6.97 % 0.68 % +0.21 (+1.03%) USD0.02B

Frequently Asked Questions About ALT Stock

Based on ratings from 5 analysts Altimmune Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 3 buy, sell and 1 hold ratings.

Unfortunately we do not have enough data on ALT's stock to indicate if its a good dividend stock.

Based on targets from 5 analysts, the average taret price for ALT is USD 21.83 over the next 12 months. The maximum analyst target price is USD 28 while the minimum anlayst target price is USD 6.

ALT stock's Price/Earning ratio is 1.82. Our analysis grades ALT stock's Price / Earning ratio at D. This means that ALT stock's Price/Earning ratio is above 36% of the stocks in the Biotechnology sector in the NSD exchange. Based on this ALT may be fairly valued for its sector

The last closing price of ALT's stock was USD 4.95.

The most recent market capitalization for ALT is USD 0.54B.

Based on targets from 5 analysts, the average taret price for ALT is projected at USD 21.83 over the next 12 months. This means that ALT's stock price may go up by +341.08% over the next 12 months.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...